Abstract 537P
Background
Pulmonary metastasectomy is a commonly performed operation, but with inconclusive evidence for effectiveness. The aim of this study is to investigate the patient outcome after pulmonary metastasectomy in sarcoma patients with pulmonary metastases.
Methods
We retrospectively reviewed patients undergoing pulmonary metastasectomy for metastatic soft tissue and bone sarcomas in a single center. Treatment-free interval (TFI) was defined as the duration from the last date of primary tumor treatment to pulmonary metastasectomy. Recurrence-free interval (RFI), defined as the time from pulmonary metastasectomy to identification of new pulmonary metastasis, was calculated to determine freedom from lung recurrence. Post-metastasectomy survival (PMS) was defined as the time from pulmonary metastasectomy to death. Kaplan-Meier plots and Log-rank test were used to identify prognostic factors.
Results
Data of 102 patients were include in the analysis. In the RFI analysis, 77.4% patients (79/102) developed new pulmonary metastasis after pulmonary metastasectomy, with a median duration of 8.9 months. The 2-year freedom from lung recurrence was 23.6% and 51.9% in patients with TFI less than 12 months and TFI more than 12 months, respectively (p = 0.040). In the PMS analysis, the extrathoracic recurrence (p = 0.004) and TFI, but not primary site tumor recurrence, were significant prognostic factors. The 2 and 5-year PMS rates were 68.5% and 38.1%, respectively, in patients in patients with TFI less than 12 months, compared to 80.3% and 67.6%, respectively, in patients with TFI more than 12 months (p = 0.028).
Conclusions
A significant proportion (77.4%) of patients developed lung recurrences after pulmonary metastasectomy for sarcoma. Patients with TFI more than 12 months were associated with higher rate of freedom from lung recurrence and better PMS after pulmonary metastasectomy for sarcoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract